The center, based in the eastern Hangzhou region, is the New York-based drug company’s first biotech center in Asia.
The facility, expected to be completed by 2018, will develop biologic drugs and lower-cost biosimilars. Pfizer plans to work closely with local regulators to bring the drugs to market as soon as possible, according to a statement on its website.
Pfizer’s plans depict a recent trend by pharma industry giants to develop new strategies to tap into China’s healthcare market, which is estimated to be around $185 billion by 2018.
More articles on supply chain:
Leukocyte reduction devices recalled for faulty filters
5 latest FDA approvals
Medtronic acquires HeartWare for $1.1B
